NCT03245710

Brief Summary

This study investigates the efficacy and mechanism of traditional Chinese medicine formula power product in the treatment of osteopenia in patients with pain. Half of participants will receive Chinese medicine formula power product, while the other half will receive a placebo.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 8, 2017

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

February 24, 2017

Completed
6 months until next milestone

First Posted

Study publicly available on registry

August 10, 2017

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 7, 2020

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 7, 2021

Completed
Last Updated

April 29, 2020

Status Verified

April 1, 2020

Enrollment Period

3.2 years

First QC Date

February 24, 2017

Last Update Submit

April 27, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain on the visual-analogue scales (VAS) for back and legs.

    A VAS is a 100-mm-long horizontal line that is anchored by word descriptors at each end (no pain and worst pain possible). The patient selects the point on the line that best represents his or her perception of their pain level.

    baseline and week 12

Study Arms (2)

Zhibai Dihuang powder

EXPERIMENTAL

Arm: Experimental: Zhibai Dihuang Formula powder Zhibai Dihuang Formula powder: Traditional Chinese medicine formula powder product 5g by mouth, after meal, 3 times in one day for 12 weeks

Dietary Supplement: Zhibai Dihuang powder

placebos

PLACEBO COMPARATOR

Arm: placebo Comparator placebos 5g by mouth after meal, 3 times in one day for 12 weeks

Other: Placebos

Interventions

starch

placebos
Zhibai Dihuang powderDIETARY_SUPPLEMENT

the Traditional Chinese Medicine Formula Powder Product

Zhibai Dihuang powder

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • aged 50 years or older.
  • VAS score≧4.0 in a week.
  • bone mineral density (BMD) of all participants was -2.5 or below.

You may not qualify if:

  • diabetes.
  • thyroidism function disorder.
  • parathyroidism function disorder.
  • liver or kidney function disorder.
  • ovariectomy
  • rheumatoid arthritis.
  • bone cancer.
  • ever used hormone agent within 6 months before assignment to treatment.
  • ever used steroids more than 3 months before assignment to treatment.
  • ever used analgesics, excepted acetaminophen, more than 1 week before assignment to treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

WanFangH

Taipei, 116, Taiwan

RECRUITING

MeSH Terms

Conditions

Bone Diseases, Metabolic

Condition Hierarchy (Ancestors)

Bone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Chung-Yu Huang, MD

    Taipei Municipal WanFang Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chung-Yu Huang, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 24, 2017

First Posted

August 10, 2017

Study Start

February 8, 2017

Primary Completion

May 7, 2020

Study Completion

March 7, 2021

Last Updated

April 29, 2020

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will not share

Locations